{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:41Z","timestamp":1761059561583},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.eimc.2013.04.023","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T22:15:20Z","timestamp":1373494520000},"page":"48-57","source":"Crossref","is-referenced-by-count":12,"title":["An\u00e1lisis farmacocin\u00e9tico-farmacodin\u00e1mico en microbiolog\u00eda: herramienta para evaluar el tratamiento antimicrobiano"],"prefix":"10.1016","volume":"33","author":[{"given":"Andr\u00e9s","family":"Canut Blasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Aguilar Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cobo Reinoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jos\u00e9","family":"Gim\u00e9nez Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2013.04.023_bib0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JB.59.5.625-643.1950","article-title":"The effective concentrations of penicillin in vitro and in vivo for streptococci, pneumococci, and Treponema pallidum","volume":"59","author":"Eagle","year":"1950","journal-title":"J Bacteriol"},{"key":"10.1016\/j.eimc.2013.04.023_bib0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM195303192481201","article-title":"\u2018Continuous\u2019 vs \u2018discontinuous\u2019 therapy with penicillin: The effect of the interval between injections on therapeutic efficacy","volume":"248","author":"Eagle","year":"1953","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.04.023_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic-pharmacodynamic parameters: Rationale for antibacterial dosing in mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.04.023_bib0020","unstructured":"Guideline for the Evaluation of Medicinal Products indicated for Treatmenet of Bacterial Infections. Agencia Europea del Medicamento (EMA). CPMP\/EWP\/558\/95, rev. 2, febrero 2010."},{"key":"10.1016\/j.eimc.2013.04.023_bib0025","first-page":"203","article-title":"\u2018S\u2019 does not mean success: The importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection","volume":"69","author":"Gillespie","year":"2005","journal-title":"Conneticut Medicine"},{"key":"10.1016\/j.eimc.2013.04.023_bib0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijantimicag.2008.03.015","article-title":"Pharmacokinetics\/pharmacodynamics of antibacterials in the Intensive Care Unit: Setting appropriate dosing regimens","volume":"32","author":"Scaglione","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2013.04.023_bib0035","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","article-title":"Antibiotic resistance-what's dosing got to do with it","volume":"36","author":"Roberts","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eimc.2013.04.023_bib0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.42.3.521","article-title":"Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy","volume":"42","author":"Thomas","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.04.023_bib0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2013.04.023_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eimc.2011.09.018","article-title":"Programas de optimizaci\u00f3n de uso de antimicrobianos (PROA) en hospitales espa\u00f1oles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH","volume":"30","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.04.023_bib0055","series-title":"Gu\u00eda de Terap\u00e9utica Antimicrobiana","author":"Mensa","year":"2012"},{"key":"10.1016\/j.eimc.2013.04.023_bib0060","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ijantimicag.2010.11.011","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) considerations in the management of Gram-positive bacteraemia","volume":"36S","author":"Scaglione","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2013.04.023_bib0065","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eimc.2013.04.023_bib0070","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s10096-012-1560-7","article-title":"Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigeciclyne and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries","volume":"31","author":"Canut","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2013.04.023_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/dkm536","article-title":"Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic\u2013pharmacodynamic models with Monte Carlo simulation","volume":"61","author":"Frei","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2013.04.023_bib0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijantimicag.2012.06.005","article-title":"Comparison of antimicrobial pharmacokinetic\/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria","volume":"40","author":"As\u00edn","year":"2012","journal-title":"Intern J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2013.04.023_bib0085","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: Implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.eimc.2013.04.023_bib0090","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/AAC.00782-08","article-title":"Prospective observational study of the impact of VIM-1 metallo-\u03b2-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections","volume":"53","author":"Daikos","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.04.023_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MRM.0b013e3283094bca","article-title":"Gaps in antibiotic development: The post-marketing task","volume":"19","author":"Aguilar","year":"2008","journal-title":"Rev Med Microbiol"},{"key":"10.1016\/j.eimc.2013.04.023_bib0100","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1128\/AAC.46.5.1340-1344.2002","article-title":"Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model","volume":"46","author":"Casal","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.eimc.2013.04.023_bib0105","first-page":"29","article-title":"Strategies to minimize the development of antibiotic resistance","volume":"9","author":"Baquero","year":"1997","journal-title":"J Chemother"},{"key":"10.1016\/j.eimc.2013.04.023_bib0110","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1574-6976.2011.00295.x","article-title":"Emergence and spread of antibiotic resistance following exposure to antibiotics","volume":"35","author":"Cant\u00f3n","year":"2011","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.eimc.2013.04.023_bib0115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.04.023_bib0120","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/AAC.05360-11","article-title":"Dosing regimen matters: The importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target","volume":"56","author":"Martinez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.04.023_bib0125","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jac\/dkg401","article-title":"Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: Related changes in susceptibility, resistance frequency and bacterial killing","volume":"52","author":"Zinner","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2013.04.023_bib0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"CID"},{"key":"10.1016\/j.eimc.2013.04.023_bib0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2013.04.023_bib0140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.04.023_bib0145","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: Proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2013.04.023_bib0150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bmj.312.7027.338","article-title":"Single or multiple daily doses of aminoglycosides: A meta-analysis","volume":"312","author":"Barza","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2013.04.023_bib0155","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/clinids\/24.5.786","article-title":"A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides","volume":"24","author":"Bailey","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.04.023_bib0160","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/CCM.0b013e3181a0054d","article-title":"A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eimc.2013.04.023_bib0165","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: A systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.04.023_bib0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2110-5820-2-22","article-title":"Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?","volume":"2","author":"Van Herendael","year":"2012","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.eimc.2013.04.023_bib0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: Systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2013.04.023_bib0180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/cc7774","article-title":"Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock \u2014 does the dose matter?","volume":"13","author":"Pea","year":"2009","journal-title":"Crit Care"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X13001602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X13001602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T10:50:53Z","timestamp":1596106253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X13001602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0213005X13001602"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2013.04.023","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}